908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith Sells 10,236 Shares

908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith sold 10,236 shares of 908 Devices stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $2.34, for a total transaction of $23,952.24. Following the completion of the transaction, the chief financial officer now owns 109,870 shares in the company, valued at approximately $257,095.80. This represents a 8.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

908 Devices Stock Performance

Shares of NASDAQ:MASS traded up $0.08 during trading hours on Tuesday, hitting $2.37. 264,671 shares of the company’s stock traded hands, compared to its average volume of 1,063,058. 908 Devices Inc. has a 52 week low of $1.81 and a 52 week high of $7.91. The company’s fifty day simple moving average is $2.36 and its two-hundred day simple moving average is $3.29. The company has a market cap of $82.52 million, a price-to-earnings ratio of -1.34 and a beta of 0.98.

Analyst Ratings Changes

MASS has been the topic of a number of research analyst reports. Leerink Partners reissued a “market perform” rating and set a $4.00 price objective (down previously from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Leerink Partnrs downgraded shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Stephens reiterated an “overweight” rating and set a $6.00 price objective on shares of 908 Devices in a research note on Wednesday, January 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of 908 Devices in a report on Saturday. Finally, Stifel Nicolaus dropped their price objective on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.33.

Hedge Funds Weigh In On 908 Devices

Large investors have recently made changes to their positions in the business. 49 Wealth Management LLC boosted its holdings in shares of 908 Devices by 16.2% in the third quarter. 49 Wealth Management LLC now owns 31,099 shares of the company’s stock worth $108,000 after buying an additional 4,343 shares during the period. State Street Corp lifted its position in shares of 908 Devices by 1.2% in the third quarter. State Street Corp now owns 479,044 shares of the company’s stock worth $1,662,000 after purchasing an additional 5,704 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of 908 Devices by 1.2% in the third quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock worth $1,970,000 after purchasing an additional 6,634 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of 908 Devices in the third quarter worth approximately $36,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of 908 Devices in the third quarter worth approximately $45,000. Institutional investors own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.